Navigation Links
MedQuist Names Dominick J. Golio as Chief Financial Officer
Date:4/15/2009

MOUNT LAUREL, N.J., April 15 /PRNewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ) today announced it has named Dominick J. Golio as its new Chief Financial Officer. He joined MedQuist on April 13, 2009.

In his role as MedQuist's new CFO, Golio is responsible for directing all financial operations and controls, in addition to financial planning, treasury, financial analysis, investor relations, tax, and financial reporting. "Dominick's broad experience as a Chief Financial Officer will contribute significantly to the overall strategy of the company," said Peter Masanotti, President and CEO. "He has a successful track record in developing high performance teams and brings an exemplary combination of business judgment, professional skills and integrity to MedQuist."

Golio, 63, was most recently the North America Chief Financial Officer for D & M Holdings NA, a Bain Capital Holdings Portfolio Company. Prior to joining D & M Holdings, Golio was Senior Vice President/CFO at Belco Oil & Gas Corporation, an energy company previously listed on the New York Stock Exchange. He also held CFO positions at Millmaster Onyx Group, AEG Corporation NA, and Case Pomeroy & Company.

Golio holds a B.A. and Master's degree in Business Administration from Pace University and is a Certified Public Accountant.

MedQuist is a leading provider of medical transcription services, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions -- including mobile voice capture devices, speech recognition, Web-based workflow platforms, and a global network of medical editors -- help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit www.medquist.com.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE MedQuist Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedQuist Re-launches New, Improved Web Site
2. MedQuist Updates Status of Outstanding SEC Filings
3. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
4. MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders
5. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
6. MedQuist Announces Appointment of Brian ODonoghue and Mark E. Schwarz to its Board of Directors
7. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
8. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
9. MedQuist Technology Solutions to Power Documentation Workflow at New England Facility
10. MedQuist to Get New Majority Stakeholder
11. MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... already work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement ... and cost of the care members and patients receive. The agreement also signifies ...
(Date:7/24/2017)... Switzerland (PRWEB) , ... July 24, 2017 , ... Anyone ... to weigh a watermelon, nor would a pharmacist using that same scale to dispense ... risk someone’s health. , These illustrations show why it is important to have ...
(Date:7/24/2017)... ... July 24, 2017 , ... A new report ... on delivering end-to-end sleep health care at scale, indicates record-breaking adherence results for ... rates for positive airway pressure (PAP) therapy, the most widely utilized treatment for ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created in collaboration with ... StorErotica Awards to be consumer voted. The Magic Wand Rechargeable won in stiff ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, ... **, Aug. 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird ... scrutiny and growing demands to track and report adverse events place even greater ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
Breaking Medicine Technology: